The new Boston, MA-based biotech, Pyxis Oncology, believes focusing on a better understanding of tumor-reactive T-cells from the core of growing tumors, rather than relying on older approaches originating largely from infectious disease inflammation models, could lead to new families of antibody-based immuno-oncology therapies.
The tumor micro-environment has been a hot area of research for a number of years, but Pyxis Oncology was founded...






